LGD-4033 Powder 1g

Description

LGD-4033 Powder — Research Overview

LGD-4033 (Ligandrol, VK5211) is a non-steroidal selective androgen receptor modulator developed by Ligand Pharmaceuticals. It is among the most studied SARMs, having progressed through Phase II clinical trials in hip fracture recovery, where it demonstrated significant lean mass gains at low oral doses.

Mechanism of Action

LGD-4033 binds the androgen receptor with high affinity (Ki ~1nM), comparable to testosterone, but with tissue selectivity favouring muscle and bone over prostate and seminal vesicles. It activates AR-dependent transcription of anabolic genes — including IGF-1, follistatin, and myosin heavy chain isoforms — in skeletal muscle. In bone, it promotes osteoblast activity and cortical bone mineral density in ovariectomised rodent models.

Powder Format for Research

Powder format enables precise formulation for pharmacokinetic studies, bioavailability research, and in vitro receptor binding assays. LGD-4033 is readily soluble in DMSO (≥50mg/mL) and ethanol. For oral gavage in rodent studies, it is typically suspended in 1% methylcellulose or PEG400/water solutions at 1–10mg/kg doses.

Clinical Context

The Phase II hip fracture trial (Bhasin et al.) demonstrated 1mg/day LGD-4033 increased lean body mass by ~1.2kg at 12 weeks with no significant change in PSA or haematocrit, establishing a clinical safety reference point for AR selectivity research.

Purity: ≥98% (HPLC verified) | Format: Lyophilised powder | Quantity: 1g

For research use only. Not for human consumption.